Norgine today
The most prominent contributor to Norgine's growth is MOVICOL®, which is the world’s leading prescription laxative.
Norgine is one of a handful of independent pharmaceutical companies with a genuinely pan-European base, having successfully developed during its104 year history to become a specialty pharmaceutical powerhouse.
At the end of 2009, Norgine employed around 1200 staff with over 400 in Sales and Marketing and around 500 in Manufacturing. They are supported by a strong Development team, Medical and Regulatory Affairs expertise and appropriate administrative functions. In 2009 Norgine’s total revenue increased to €257 million, with net product sales increasing by 9% to €253 million. On a constant currency basis, Norgine’s net product sales increased by just over 11%, the 23rd consecutive year of double digit sales growth on this basis. The most prominent contributor to Norgine's growth is MOVICOL, which is the world’s leading prescription laxative. Sales of Norgine’s bowel cleansing preparation, MOVIPREP®, are also growing rapidly. Launched in the US in 2006 and in Europe in 2007, MOVIPREP is already Norgine’s second largest product and is the European bowel cleansing sector leader and the leading brand worldwide.
Norgine's focus is pharmaceutical products that address 
significant unmet clinical need in areas such as gastroenterology, hepatology and supportive care. We currently market a number of products in our key therapeutic areas, e.g. MOVICOL for the treatment of chronic constipation and faecal impaction, MOVIPREP for bowel preparation prior to colonoscopy, FIVASA® for the treatment of ulcerative colitis and Crohn's Disease, XIFAXAN® for the treatment of travellers diarrhoea and ORAMORPH® for the treatment of moderate to severe pain.
Norgine has a highly active Development function and currently has more than 10 products at various stages of clinical development in our core areas of gastroenterology and hepatology. The Company is undertaking a significant clinical development programme both in the USA and Europe with NRL 972, a liver diagnostic. NRL 972 promises to provide a real advance in the diagnosis and staging of a variety of liver diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and cirrhosis, to the benefit of patients, their carers and society at large. We are also looking to further develop our new pipeline products such as CAMETOR® for the treatment of obesity, ZEGERID® an immediate release omeprazole that Norgine have licensed in from Santarus and TZP101 recently licensed in from Tranzyme.